Everything below concerns Fragment designation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-10. Numbers and descriptions here follow the published literature rather than marketing material.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
All Mycobacteria – M. tuberculosis, M. leprae, M. smegmatis and atypical mycobacteria. Certain Actinobacteria (especially aerobic ones in the order Mycobacteriales) with mycolic acid in their cell wall; not to be confused with Actinomyces, which is a non-acid-fast genus of actinomycete. Note that Streptomyces do not contain mycolic acid. Nocardia (weakly acid-fast; resists decolorization with weaker acid concentrations) Rhodococcus Gordonia Tsukamurella Dietzia Head of sperm Bacterial spores, see Endospore Legionella micdadei Certain cellular inclusions e.g. Cytoplasmic inclusion bodies seen in Neurons in layer 5 of cerebral cortex neuronal ceroid lipofuscinosis (Batten disease). Nuclear inclusion bodies seen in Lead poisoning Bismuth poisoning. Oocysts of some coccidian parasites in faecal matter, such as: Cryptosporidium parvum, Isospora belli Cyclospora cayetanensis. A few other parasites: Sarcocystis Taenia saginata eggs stain well but Taenia solium eggs don't (can be used to distinguish) Hydatid cysts, especially their "hooklets" stain irregularly with ZN stain but emanate bright red fluorescence under green light, and can aid detection in moderately heavy backgrounds or with scarce hooklets. Fungal yeast forms are inconsistently stained with Acid-fast stain which is considered a narrow spectrum stain for fungi. In a study on acid-fastness of fungi, 60% of blastomyces and 47% of histoplasma showed positive cytoplasmic staining of the yeast-like cells, and Cryptococcus or candida did not stain, and very rare staining was seen in Coccidioides endospores.
=== Sensitivity === Detection limit is defined as the lowest amount of explosive matter a detector can detect reliably. It is expressed in terms of nano-grams (ng), pico-grams (pg) or femto-grams (fg) with fg being better than pg better than ng. It can also be expressed in terms of parts per billion (ppb), parts per trillion (ppt) or parts per quadrillion (ppq). Sensitivity is important because most explosives have a low vapor pressure . The detector with the highest sensitivity is the best in detecting vapors of explosives reliably.
=== Ultra-low temperature refrigerators === "Ultra-cold" or "ultra-low temperature (ULT)" (typically −80 or −86 °C [−112 or −123 °F]) freezers, as used for storing biological samples, also generally employ two stages of cooling, but in cascade. The lower temperature stage uses methane, or a similar gas, as a refrigerant, with its condenser kept at around −40 °C by a second stage which uses a more conventional refrigerant. For much lower temperatures, laboratories usually purchase liquid nitrogen (−196 °C [−320.8 °F]), kept in a Dewar flask, into which the samples are suspended. Cryogenic chest freezers can achieve temperatures of down to −150 °C (−238 °F), and may include a liquid nitrogen backup.
=== Guest === Ts Madison as Shirley (season 1) Don Curry as Tony Free (season 3) Syleena Johnson as Naomi (season 3) Jaleel White as Max Jefferson (season 3) Lisa Vidal as Michelle (season 3) Essence Atkins as Charnelle (season 3) Marla Gibbs as Miss Pearl (season 3) Debra Wilson as Veronica (season 4) Flex Alexander as Pastor Jenkins (season 4) Golden Brooks as Tanya (season 4) Kellie Williams as Lisa (season 4) Raven-Symoné as Lady Tyra (season 5) Tisha Campbell as Detective Sheila Jackson (season 5) Tristan Wilds as Professor Christian DeWalt (season 5) Keith Robinson as James Freeman (season 5) Sandra Caldwell as Yolanda (season 5) Loretta Devine as Carol (season 5) SWV as themselves (season 5)
14E PATRIOT Fire Control Enhanced Operator/Maintainer 14G Air Defense Battle Management System Operator 14H Air Defense Enhanced Early Warning System Operator 14P Air and Missile Defense Crewmember 14S Avenger Crewmember 14T PATRIOT Launching Station Enhanced Operator/Maintainer 14U Air Defense Artillery Recruit 14Z Air Defense Artillery (ADA) Senior Sergeant
Sources: en.wikipedia.org
=== Colorimetrics === The use of colorimetric test kits for explosive detection is one of the oldest, simplest, and most widely used methods for the detection of explosives. Colorimetric detection of explosives involves applying a chemical reagent to an unknown material or sample and observing a color reaction. Common color reactions are known and indicate to the user if there is an explosive material present and in many cases the group of explosive from which the material is derived. The major groups of explosives are nitroaromatic explosives, nitrate ester and nitramine explosives, improvised explosives not containing nitro groups which includes inorganic nitrate based explosives, chlorate based explosives, and peroxide based explosives.
Frost-free refrigerators and freezers use electric fans to cool the appropriate compartment. This could be called a "fan forced" refrigerator, whereas manual defrost units rely on colder air lying at the bottom, versus the warm air at the top to achieve adequate cooling. The air is drawn in through an inlet duct and passed through the evaporator where it is cooled, the air is then circulated throughout the cabinet via a series of ducts and vents. Because the air passing the evaporator is supposedly warm and moist, frost begins to form on the evaporator (especially on a freezer's evaporator). In cheaper and/or older models, a defrost cycle is controlled via a mechanical timer. This timer is set to shut off the compressor and fan and energize a heating element located near or around the evaporator for about 15 to 30 minutes at every 6 to 12 hours. This melts any frost or ice build-up and allows the refrigerator to work normally once more. It is believed that frost free units have a lower tolerance for frost, due to their air-conditioner-like evaporator coils. Therefore, if a door is left open accidentally (especially the freezer), the defrost system may not remove all frost, in this case, the freezer (or refrigerator) must be defrosted. If the defrosting system melts all the ice before the timed defrosting period ends, then a small device (called a defrost limiter) acts like a thermostat and shuts off the heating element to prevent too large a temperature fluctuation, it also prevents hot blasts of air when the system starts again, should it finish defrosting early.
=== Origin and Penfold directorship === CSL was founded in 1916 as Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. Under the first director, William Penfold, CSL commenced operation in the vacant Walter and Eliza Hall Institute building at the Royal Melbourne Hospital in 1918 before moving to its purpose-built Parkville premises in the following year.
Anahuasca (ayahuasca analogue or variants). A term usually used to refer to the ayahuasca produced with other plant species as sources of DMT (e.g., Mimosa hostilis) or β-carbolines (e.g., Peganum harmala). Pharmahuasca (pharmaceutical ayahuasca). This indicates the pills produced from freebase DMT, synthetic harmaline, MAOI medications (such as moclobemide) and other isolated or purified compounds or extracts.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.